Skip to content

Compounds · Skin & hair · Treatment of erythropoietic protoporphyria and photosensitivity disorders

Afamelanotide

Full protocol

Melanotan I, MT-I, CUV1647, Scenesse

Synthetic α-MSH analog approved (Scenesse) for erythropoietic protoporphyria, a rare light-sensitivity disorder. Boosts eumelanin production to extend pain-free sun exposure.

0.25 mg twice weekly, then weekly

Research score 85/100. Reference only, not a prescription.

  • Skin Health
  • Melanin Production
  • Photoprotection
  • Pain Relief
  • Anti-inflammatory
US status
FDA Approved
Approval
FDA + EMA Approved
Evidence
FDA approved (Scenesse) for EPP. Implant delivery.
Research score
85 / 100
Indication
Photoprotection
Origin
Australia
Source category
Skin & Dermatology
Status group
Approved / prescription

Mechanism

Agonizes melanocortin-1 receptors on melanocytes, raising cAMP and driving MITF-linked tyrosinase activity toward eumelanin over pheomelanin. Also curbs NF-κB-driven inflammation and supports DNA-repair and antioxidant responses.

Safety file

Implant-site reactions are common, along with nausea, headache, and darkened skin. Anaphylaxis is rare.

  • Nausea
  • Headache
  • Skin darkening
  • Injection site reactions
  • Fatigue

Important: The only approved form of afamelanotide is Scenesse, a 16 mg implant placed by a clinician every 2 months for a rare light-sensitivity disorder (EPP). Injectable Melanotan-1 is unapproved; the protocol below is community practice, not a label.

Reconstitution

Concentration by vial size and water volume
Vial1 mL water2 mL water
10 mg10 mg/mL5 mg/mL
  1. Use bacteriostatic water as the diluent.
  2. Add the water slowly, letting it run down the inside wall of the vial rather than onto the powder.
  3. Swirl gently to mix, then leave it to dissolve. Do not shake.
  4. Give it a few minutes. The finished solution should be clear and colourless.

Full mixing method

Protocol

Route: Subcutaneous

Standard protocol (subcutaneous)

  • Loading: 0.25 mg (250 mcg) twice weekly for about 4 weeks, paired with gradual UV exposure (15 to 30 minutes, building up)
  • Maintenance: taper to roughly once weekly once colour develops
  • At a 2 mL fill on a 10 mg vial (5 mg/mL), 0.25 mg is a 0.05 mL draw (5 units)

Milder than Melanotan-2

  • Melanotan-1 (afamelanotide) causes much less nausea and does not have the libido or appetite effects of MT-2, so most people tolerate it more easily

Dosing detail

  • Loading: 0.25 mg twice weekly for about 4 weeks. Maintenance: about once weekly after colour develops.
  • Pair with gradual UV exposure to build the tan.
  • Reported as milder than MT-2. The Scenesse label lists nausea, headache, dizziness, fatigue and new moles.
  • Watch moles and freckles for any changes, as with any tanning peptide.

Duration

  • About 4 weeks of twice-weekly loading, then weekly maintenance.

Notes

  • Also called afamelanotide. Milder on nausea and without the libido effect of MT-2.
  • The Scenesse label advises a full-body skin check twice a year.
  • Inject subcutaneously and rotate sites.

Storage and handling

  • Keep the powdered (lyophilized) vial in a cool, dark place. Refrigerate it for longer-term storage before mixing.
  • Once reconstituted and refrigerated at 2–8 °C away from light, use the vial within 28 days.
  • Do not freeze a reconstituted vial, and keep it away from heat and sunlight.
  • If the solution turns cloudy, develops floating particles, or shows any other sign of degradation, stop using that vial.

Storage rules and when to discard